- Todos > Medicine Access and Rational Use > Financing
- Todos > Medicine Access and Rational Use > Pricing
- Todos > Quality and Safety: Medicines > Regulatory Support
- Palabras clave > access to affordable essential medicines
- Palabras clave > cost containment policies
- Palabras clave > cost-sharing mechanisms - pharmaceuticals
- Palabras clave > EU medicines regulation
- Palabras clave > marketing authorization
- Palabras clave > medicines regulatory systems
- Palabras clave > pharmaceutical expenditures - cost analysis
- Palabras clave > pharmaceutical pricing and reimbursement policies
- Palabras clave > pharmacovigilance systems
- Palabras clave > prices / pricing policy
(2016; 143 pages)
Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, Jommi C, Kaitelidou D, Kawalec P, Keskimäki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, Wouters O, Busse R. Pharmaceutical regulation in 15 European countries: Review. Health Systems in Transition, 2016; 18(5):1–118.
In the context of pharmaceutical care, policy-makers repeatedly face the challenge of balancing patient access to effective medicines with affordability and rising costs. With the aim of guiding the health policy discourse towards questions that are important to actual and potential patients, this study investigates a broad range of regulatory measures, spanning marketing authorization to generic substitution and resulting price levels in a sample of 16 European health systems (Austria, Belgium, Denmark, England, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Poland, Portugal, Scotland, Spain and Sweden).
All countries employ a mix of regulatory mechanisms to contain pharmaceutical expenditure and ensure quality and efficiency in pharmaceutical care, albeit with varying configurations and rigour. This variation also influences the extent of publicly financed pharmaceutical costs. Overall, observed differences in pharmaceutical expenditure should be interpreted in conjunction with the differing volume and composition of consumption and price levels, as well as dispensation practices and their impact on measurement of pharmaceutical costs.
No definitive evidence has yet been produced on the effects of different cost-containment measures on patient outcomes. Depending on the foremost policy concerns in each country, different levers will have to be used to enable the delivery of appropriate care at affordable prices.